Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAF01
- Development stage
- Phase 1
- Lead developer
- Statens Serum Institut
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Subcutaneous, Intranasal, Topical, Intradermal
01
Overview
CAF01 is a clinical-stage cationic liposomal adjuvant system developed by the Statens Serum Institut (SSI). It is composed of the cationic lipid dimethyl-dioctadecylammonium (DDA) bromide and the synthetic cord factor trehalose-6,6'-dibehenate (TDB). CAF01 functions as a delivery system that forms a depot at the injection site while simultaneously acting as an immunomodulator. The TDB component is a potent agonist of the macrophage-inducible C-type lectin (Mincle) receptor, which triggers the innate immune system to drive the differentiation of Th1 and Th17 cell-mediated immunity and robust antibody responses. This adjuvant has been evaluated in human clinical trials for vaccines targeting tuberculosis, HIV-1, and Chlamydia trachomatis, and has shown a favorable safety profile and strong immunogenicity.
- Other names
- Cationic Adjuvant Formulation 01Cationic Adjuvant Formulation 1DDA/TDB
02
Targets
CLEC4E (Macrophage-inducible C-type lectin receptor)
Beyond the preview
Go deeper on CAF01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAF01.